A Postdoctoral position in Pediatric Cancer research is available in the team "Signaling in Cancer Progression" (https://science.institut-curie.org/research/biology-chemistry-of-radiationscell- signaling-and-cancer-axis/umr-3347-normal-and-pathological-signaling/team-eychenepouponnot/, IC, INSERM U1021, CNRS UMR3347, University Paris Saclay) under the supervision of C. Pouponnot at the Curie Institute.
Rhabdoid tumors (RTs) are deadly aggressive pediatric cancers that arise in the brain, kidney, liver, and miscellaneous soft-tissues treated by combinations of intensive chemotherapy and radiotherapy. Our objective is to investigate the modification of the immune landscape in
RTs in response to different modalities of radiotherapy in order to better understand how radiotherapy could modulate the immune infiltrate and to determine the best combination between irradiation and immunotherapy by "checkpoint inhibitors" (CPI) in anticipation of a
Required profile :
Enthusiastic applicants must have a strong expertise in mouse experimentation including subcutaneous and orthotopic grafting, molecular biology/biochemistry (FACS, histology, RNA, proteins…). Since the project is part of a collaborative network, excellent communication skills
are required as well as ability to work with bioinformatician/computational biologist. The applicant should be able to conduct his/her research independently but also to work as team.
Solid track record is mandatory.
This project involves a collaborative network of 4 teams :
- "Signaling in Cancer progression" led by Celio Pouponnot & A. Eychène (IC/UMR3347 CNRS / U1021 INSERM/ UPSUD).
- two teams of the U830 INSERM: Josh Waterfall's team (Integrative Functional Genomics of Cancer, and the "Translational Research in Pediatric Oncology" (Franck Bourdeaut)
- "Translational Research in Immunology" team , directed by Eliane Piaggio (IC/U932 INSERM directed by Sebastian Amigorena).
Applications must include a CV with a cover letter and contacts for 2 references.
Please apply by email to: email@example.com